Media.Player

A Novel Index of Assessing Atherosclerosis Regression and Plaque Stabilization

Detailed Technology Description

UC San Diego researchers have invented a novel index of atherosclerosis regression that is determined by measuring the plasma content of oxidized phospholipids. The index could provide valuable information to physicians who would use this index to measure the efficacy of treatment with statins or new anti-atherogenic drugs.

Supplementary Information

Patent Number: US8129123B2
Application Number: US2005244300A
Inventor: Tsimikas, Sotirios | Witztum, Joseph L.
Priority Date: 5 Oct 2004
Priority Number: US8129123B2
Application Date: 5 Oct 2005
Publication Date: 6 Mar 2012
IPC Current: G01N003353
US Class: 4350071 | 43500792 | 43500794 | 436501 | 436518
Assignee Applicant: The Regents of the University of California
Title: Methods for assessing atherogenesis by determining oxidized phospholipid to apolipoprotein B ratios
Usefulness: Methods for assessing atherogenesis by determining oxidized phospholipid to apolipoprotein B ratios
Summary: The method is useful for determining whether therapy is effective for treating coronary artery disease (claimed).
Novelty: Determining whether therapy is effective for treating coronary artery disease, by determining oxidized phospholipid and apoB levels in samples obtained before and after administration of therapy, and calculating atherogenesis index

Industry

Disease Diagnostic/Treatment

Sub Category

Other Disease

Application No.

8129123

Others

Related Materials

1. See the published article INNOVATION: From lab to product: a blood test's story.
2. Fraley AE, Schwartz GG, Olsson AG, Kinlay S, Szarek M, Rifai N, Libby P, Ganz P, Witztum JL, Tsimikas S; MIRACL Study Investigators. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering) trial. J Am Coll Cardiol. 2009 Jun 9;53(23):2186-96.

Tech ID/UC Case

19643/2005-037-0

Related Cases

2005-037-0, 2009-236-1, 2009-236-2

*Abstract

Oxidized phospholipids (OxPL) are present in vessel walls and have been shown to be pro-inflammatory and pro-atherogenic. When cholesterol is lowered by drugs or diet, the plasma levels of the OxPL increase, suggesting a movement or clearance of the phospholipids from the vessel wall into the circulation. This activity, then, is an important indicator that plaque stabilization and/or reduction is occurring. Currently, there are no plasma biomarkers that reflect the amount of plaque or determine the benefits of anti-atherosclerotic therapies.

*IP Issue Date

Mar 6, 2012

*Principal Investigator

Name: Sotirios Tsimikas

Department:

Name: Joseph Witztum

Department:

Country/Region

USA